<DOC>
	<DOCNO>NCT01724346</DOCNO>
	<brief_summary>An Open-label Extension Study Patients 65 Years Older Chronic Lymphocytic Leukemia ( CLL ) Small Lymphocytic Lymphoma ( SLL ) Who Participated Study PCYC-1115-CA ( PCI-32765 versus Chlorambucil )</brief_summary>
	<brief_title>Open-label Extension Study Patients 65 Years Older With Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>Study PCYC-1116-CA open-label , multicenter extension Study PCYC 1115-CA ( RESONATEâ„¢-2 , parent study ) , run concurrently parent study . A patient transfer PCYC-1116-CA Independent Review Committee ( IRC ) confirmation disease progression ( PD ) parent study closure parent study sponsor , whichever come first . After PD , selection second-line therapy , clinically indicate , discretion investigator include second-line PCI-32765 ( patient randomize chlorambucil parent study also meet criteria second-line PCI-32765 therapy ) , second-line chlorambucil ( patient randomize PCI-32765 parent study ) , therapy . Assessments extension study vary depend treatment patient randomize parent study , disease-progression status transfer extension study , plan treatment extension study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>1 . Randomized parent study , PCYC1115CA 2 . Informed consent Study PCYC1116CA 3 . IRCconfirmed PD parent study PCYC1115CA closure parent study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CLL , SLL</keyword>
</DOC>